miRagen Therapeutics Publishes Data Demonstrating that Therapeutic Dosing of miR-15 Family Inhibitor Protects Against Ischemic Injury to the Heart
BOULDER, Colo.--(BUSINESS WIRE)--MiRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research demonstrates that microRNA-15 (miR-15) is upregulated in response to ischemic damage in two important model systems and contributes to cardiovascular disease by regulating heart muscle cell death following a heart attack. The research was conducted by miRagen scientists in collaboration with researchers at the University of Texas Southwestern Medical Center and University of Miami Miller School of Medicine.